The Top 5 Biosimilar Articles for the Week of January 23

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 23, 2023.

Number 5: IQVIA’s Global Use of Medicines Report for 2023 has revealed increased uptake of biosimilars around the world and predicted that biosimilars could generate nearly $300 billion in savings by 2027.

Number 4: As part of a series of interviews, Kyung-Ah Kim, executive vice president of Samsung Bioepis, offered insight into how developers view the current biosimilars market, the relevance of interchangeability, and the usefulness of clinical efficacy testing.

Number 3: Patent litigators from Fish & Richardson, an intellectual property law firm, regaled audiences during a webinar covering all the big biosimilar regulatory and legal decisions throughout 2022, including updates on patent disputes and antitrust investigations.

Number 2: Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, detailed the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected to shift over the next 5 years.

Number 1: Alteogen and Alvotech announced updates for their respective license partnerships; Samsung Bioepis sped up interchangeability study for its adalimumab biosimilar; Dong-A ST shared positive phase 3 results for its ustekinumab biosimilar.

To read all of these articles and more, visit centerforbiosimilars.com.